[Portfolio]

Protara Therapeutics

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases.

Protara’s lead cell-based therapy, TARA-002, is being tested for treatment of non-muscle invasive bladder cancer (NMIBC) in an ongoing Phase 2 trial. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Back to portfolio